KELLY RIVERA: Open Payments
NPI 1134900012 · WORCESTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,310 in 110 payments from 14 companies in 2025. Trend: 2023 $33 · 2024 $2,172 · 2025 $2,310
Food & beverage: $2,309Education: $1
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 22 | $388 |
| Alkermes, Inc. | 14 | $308 |
| Teva Pharmaceuticals USA, Inc. | 9 | $297 |
| E.R. Squibb & Sons, L.L.C. | 6 | $271 |
| ABBVIE INC. | 21 | $238 |
| Vanda Pharmaceuticals Inc. | 9 | $174 |
| Janssen Pharmaceuticals, Inc | 5 | $153 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $140 |
| Lundbeck LLC | 5 | $114 |
| Axsome Therapeutics, Inc. | 3 | $67 |
Products named: REXULTI, COBENFY, AUSTEDO XR, VRAYLAR, FANAPT, ARISTADA, CAPLYTA, VIVITROL.
Industry payments across MA — which companies pay providers there.
